TY - JOUR T1 - Tumor Detection of <sup>18</sup>F-PSMA-1007 in the Prostate Gland in Patients with Prostate Cancer Using Prostatectomy Specimens as Reference Method JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1735 LP - 1740 DO - 10.2967/jnumed.121.261993 VL - 62 IS - 12 AU - Elin Trägårdh AU - Athanasios Simoulis AU - Anders Bjartell AU - Jonas Jögi Y1 - 2021/12/01 UR - http://jnm.snmjournals.org/content/62/12/1735.abstract N2 - Prostate-specific membrane antigen (PSMA) radiopharmaceuticals used with PET/CT are a promising tool for managing patients with prostate cancer. This study aimed to determine the accuracy of 18F-PSMA-1007 PET/CT for detecting tumors in the prostate gland using radical prostatectomy specimens as a reference method and to determine whether a correlation exists between 18F-PSMA-1007 uptake and the International Society of Urological Pathology grade and prostate specific antigen (PSA) level at diagnosis. Methods: Thirty-nine patients referred for 18F-PSMA-1007 PET/CT for initial staging and who underwent radical prostatectomy within 4 mo were retrospectively included. Uptake of 18F-PSMA-1007 indicative of cancer was assessed, and SUVmax and total lesion uptake were calculated for the index tumor. Histopathology was assessed from radical prostatectomy specimens. True-positive, false-negative, and false-positive lesions were calculated. Results: In 94.9% of patients, the index tumor was correctly identified with PET. SUVmax was significantly higher in the tumors than in the normal prostate tissue, but no significant differences were found between different International Society of Urological Pathology grades and SUVmax. There was a poor correlation between PSA at diagnosis and SUVmax (r = 0.23) and moderate agreement between PSA at diagnosis and total lesion uptake (r = 0.67). When all tumors (also nonindex tumors) were considered, many small tumors (∼1–2 mm) were not detected with PET. Conclusion: 18F-PSMA-1007 PET/CT performs well in correctly identifying the index tumor in patients with intermediate- to high-risk prostate cancer. Approximately 5% of the index tumors were missed by PET, a finding that agrees with previous studies. ER -